dulaglutide vs tirzepatide Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function Tirzepatide Offers Superior Kidney Protection

A., Weiss R

have immune disorders

The neuroprotective mechanisms identified - reduction of oxidative stress, modulation of inflammatory cytokines, enhancement of nerve growth factor - are theoretically sound

SWOT Snapshot (Quick Take): Strength: First-in-class weekly insulin with strong efficacy Weakness: Limited dosing flexibility vs daily insulin Opportunity: Adherence-driven market expansion & GLP-1 combos Threat: Physician inertia + competitive long-acting pipelines

Drug and Health Product Submissions Under Review (SUR)

These medicines help manage blood sugar and change some bodily functions such as delaying gastric (stomach) emptying, increasing insulin release from the pancreas, preventing glucose (sugar) from going into the bloodstream, and reducing appetite